GT Gain Therapeutics SA GANX · Stock Open GT Gain Therapeutics SA in new tab
GT Gain Therapeutics SA Analysis (GANX)
Is GT Gain Therapeutics SA a good investment? GT Gain Therapeutics SA (GANX) is currently trading at 1.83 USD. Market analysts have a consensus price target of 7.20 USD. This suggests a potential upside from current levels.
Earnings Schedule: GT Gain Therapeutics SA is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -0.55.
Investor FAQ
Does GT Gain Therapeutics SA pay a dividend?
No, it does not currently pay a dividend.
What asset class is GT Gain Therapeutics SA?
GT Gain Therapeutics SA is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -0.50.
Company Profile
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
Community Discussion